PubMed

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG.

Diabetes Care. 2002 Jul;25(7):1198-202.PMID: 12087019 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.

Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG.

Am J Cardiol. 2001 Jan 1;87(1):44-8.PMID: 11137832 [PubMed - indexed for MEDLINE]Related articles

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS.

J Cardiovasc Risk. 1999 Apr;6(2):113-6.PMID: 10353071 [PubMed - indexed for MEDLINE]Related articles

Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.

Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R.

Am Heart J. 2002 Oct;144(4):E6.PMID: 12360175 [PubMed - indexed for MEDLINE]Related articles

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.

Metabolism. 2005 May;54(5):677-81.PMID: 15877299 [PubMed - indexed for MEDLINE]Related articles

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.

Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS.

Eur J Clin Pharmacol. 2000 Dec;56(9-10):631-5.PMID: 11214768 [PubMed - indexed for MEDLINE]Related articles

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.

Exp Clin Endocrinol Diabetes. 2004 May;112(5):241-7.PMID: 15146369 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.

Iovine C, Lilli S, Gentile A, Patti L, Di Marino L, Cipriano P, Riccardi G, Rivellese AA.

Eur J Clin Invest. 2006 Aug;36(8):560-5.PMID: 16893378 [PubMed - indexed for MEDLINE]Related articles

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.

Lemieux I, Salomon H, Després JP.

Ann Med. 2003;35(6):442-8.PMID: 14572169 [PubMed - indexed for MEDLINE]Related articles

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.

Diabetes Atorvastin Lipid Intervention (DALI) Study Group.

Diabetes Care. 2001 Aug;24(8):1335-41.PMID: 11473066 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.

Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.

Metabolism. 2007 Nov;56(11):1534-41.PMID: 17950105 [PubMed - indexed for MEDLINE]Related articles

[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]

Li XP, Duan J, Zhao SP, Tan MY, Xu ZM, Zhang DQ.

Zhonghua Yi Xue Za Zhi. 2006 Sep 12;86(34):2399-403. Chinese. PMID: 17156651 [PubMed - indexed for MEDLINE]Related articles

Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.

Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.

Clin Ther. 2004 Oct;26(10):1599-607.PMID: 15598476 [PubMed - indexed for MEDLINE]Related articles

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.

Després JP, Lemieux I, Salomon H, Delaval D.

J Intern Med. 2002 Jun;251(6):490-9.PMID: 12028504 [PubMed - indexed for MEDLINE]Related articles

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.

McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM.

Am J Med. 1998 Feb;104(2):137-43.PMID: 9528731 [PubMed - indexed for MEDLINE]Related articles

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.

Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group.

Am Heart J. 2004 Sep;148(3):447-55.PMID: 15389231 [PubMed - indexed for MEDLINE]Related articles

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG.

Curr Med Res Opin. 2002;18(4):220-8.PMID: 12201623 [PubMed - indexed for MEDLINE]Related articles

Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.

Chatley P, Badyal DK, Calton R, Khosla PP.

Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):217-21.PMID: 17520105 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.

Velussi M, Cernigoi AM, Tortul C, Merni M.

Diabetes Nutr Metab. 1999 Dec;12(6):407-12.PMID: 10782562 [PubMed - indexed for MEDLINE]Related articles

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.

Diabetes. 2003 Mar;52(3):803-11.PMID: 12606523 [PubMed - indexed for MEDLINE]Related articlesFree article